Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
View Patent ↗Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots.
1. A medical device comprising:
an implantable structure comprising an uncoated metallic material having a surface;
a first coating, including a combination of a rapamycin and cilostazol, in therapeutic dosages, incorporated into a first polymeric material, the first coating being affixed to the surface of the implantable structure, the combination of rapamycin and cilostazol being 45 percent by weight of the first coating and the first polymeric material being 55 percent by weight of the first coating, the first polymeric material comprising a blend of poly(ethylene-co-vinyl acetate) and polybutyl methacrylate; and
a second coating, including a second polymeric material, affixed to the first coating for controlling the elution rate of the rapamycin and the cilostazol, the second polymeric material comprising one hundred micrograms of polybutyl methacrylate.
2. The medical device according to claim 1 , wherein the implantable structure comprises a stent.
3. The medical device according to claim 1 , wherein the implantable structure comprises a stent-graft.
4. The medical device according to claim 1 , wherein the implantable structure comprises an anastomosis device.